Acacetin (5,7-dihydroxy-4'-methoxyflavone), a
flavonoid compound, has anti-peroxidative and anti-inflammatory effects. The effect of
acacetin on antimetastasis in human
prostate cancer DU-145 cells was investigated. First, the result demonstrated
acacetin could exhibit an inhibitory effect on the abilities of the adhesion, invasion, and migration by cell-matrix adhesion assay, wound-healing assay, and Boyden chamber assay. Data also showed
acacetin could inhibit the phosphorylation of
p38 mitogen-activated protein kinase (
p38 MAPK) involved in the downregulation of the expressions of
matrix metalloproteinase-2 (MMP-2),
matrix metalloproteinase-9 (MMP-9), and
urokinase-type plasminogen activator (
u-PA) at both the
protein and
mRNA levels. Next,
acacetin significantly decreased the nuclear levels of
nuclear factor kappa B (
NF-kappaB), c-Fos, and c-Jun. Also, the treatment with
acacetin to DU145 cells also leads to a dose-dependent inhibition on the binding ability of
NF-kappaB and
activator protein-1 (AP-1). Furthermore, the treatment of inhibitors specific for
p38 MAPK (
SB203580) to DU145 cells could cause reduced expressions of MMP-2, MMP-9, and
u-PA. These results showed
acacetin could inhibit the invasion and migration abilities of DU145 cells by reducing MMP-2, MMP-9, and
u-PA expressions through suppressing
p38 MAPK signaling pathway and inhibiting
NF-kappaB- or AP-1-binding activity. These findings proved
acacetin might be offered further application as an antimetastatic agent.